These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15616337)

  • 1. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM; Drusano GL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
    Santos Filho L; Eagye KJ; Kuti JL; Nicolau DP
    Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
    Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
    J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
    Tang HJ; Chuang YC; Ko WC; Chen CC; Shieh JM; Chen CH; Lee NY; Chiang SR
    Int J Infect Dis; 2012 Jan; 16(1):e34-40. PubMed ID: 22088863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
    Masterton RG; Kuti JL; Turner PJ; Nicolau DP
    J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
    Maglio D; Kuti JL; Nicolau DP
    Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
    Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
    Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
    Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
    J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
    Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
    Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.